Surgeons say the NHS 'Waiting Well' initiative now has national relevance - the project has already shown improved outcomes, reduced complications and shorter stays for patients taking part, at a time when more than seven million people in England are on waiting lists.
Led by integrated care board NHS Cheshire and Merseyside, with the support of technology partner C2-Ai and health coaching provider Surgery Hero, the programme is helping to locate and provide urgently needed support for some of the most vulnerable patients awaiting surgery.
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials. 
Northern Lincolnshire and Goole NHS Foundation Trust (NLAG) has launched new NHS App features to transform the way patients access and manage their appointments within the NHS. The programme, known as Wayfinder, is part of a national strategy led by NHS England to improve patient experience and help tackle waiting list backlogs - positioning the NHS App as the digital "front door" to NHS services. 
Genomics England has completed installation of an enterprise imaging system that will help to support a world-pioneering initiative for cancer research. The programme is linking whole genome sequencing, pathology and radiology data, in what has been described as the world’s largest multimodal cancer research platform. 
Qure.ai, one of world's leading providers of AI for healthcare, will launch its artificial intelligence (AI) playbook for radiology at this year's European Congress of Radiology. Developed with its European research partners Professor Dirk Pickuth and Dr Susanne Ohlmann-Knafo of CaritasKlinikum Saarbrücken/Germany, the playbook will provide European clinicians and radiologists with a helpful guide to understanding the business case for AI in radiology. 
One of England's integrated care systems proved the benefit of modern, cloud-telephony during the COVID-19 pandemic, and is now working with X-on on new ideas to support GPs and patients, following a roll-out to practices. Associate director of digital & technology Alicia Dunsby explains. 
Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).